← Eichor
Condition: Nash With Fibrosis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Nash With Fibrosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Blood Collection Biorepository for Liver Disease Research
Phase N/A · 1 location(s) · State University of New York at Buffalo · NCT03025074CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome
Phase N/A · 1 location(s) · Institut National de la Santé Et de la Recherche Médicale, F · NCT05623150Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
NA · 2 location(s) · Pichamol Jirapinyo, MD, MPH · NCT06138821Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease
Phase N/A · 2 location(s) · Brigham and Women's Hospital · NCT05728697Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD
Phase 4 · 1 location(s) · Getz Pharma · NCT05644717Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease
Phase N/A · 1 location(s) · Peking Union Medical College Hospital · NCT05330923Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI
Phase N/A · 1 location(s) · German Diabetes Center · NCT05046483InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Phase N/A · 1 location(s) · Dana-Farber Cancer Institute · NCT05463796A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction
Phase 3 · 356 location(s) · Akero Therapeutics, Inc · NCT06215716Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.
NA · 1 location(s) · Université de Sherbrooke · NCT06843148Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
Phase 2 · 1 location(s) · Hudson Biotech · NCT07481734An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis
Phase N/A · 1 location(s) · University of Copenhagen · NCT05335603A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Phase 3 · 361 location(s) · 89bio, Inc. · NCT06318169Digoxin In NASH (CODIN)
Phase 2 · 2 location(s) · Yale University · NCT06588699Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers
NA · 1 location(s) · Maja Thiele · NCT03308916Biomarkers in the Diagnosis and Prognosis of NAFLD
Phase N/A · 1 location(s) · University of Trieste · NCT06098417Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis
Phase N/A · 2 location(s) · Virginia Commonwealth University · NCT05720663A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Phase 2 · 30 location(s) · GlaxoSmithKline · NCT06920043Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis
NA · 1 location(s) · University of Bologna · NCT06308757A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver Fibrosis i
NA · 1 location(s) · University Hospital, Lille · NCT03472157Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis
NA · 1 location(s) · ContextVision AB · NCT07270601European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)
Phase N/A · 3 location(s) · Cambridge University Hospitals NHS Foundation Trust · NCT04190849Effectiveness of Bariatric Surgery for NAFLD/NASH
Phase N/A · 1 location(s) · Beijing Friendship Hospital · NCT04366999A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Phase 3 · 317 location(s) · 89bio, Inc. · NCT06419374LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or A
Phase 3 · 525 location(s) · Boehringer Ingelheim · NCT06632444A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfuncti
Phase 1/Phase 2 · 6 location(s) · Regeneron Pharmaceuticals · NCT05648214Risk Factors for Hepatic Inflammation, Fibrosis and Prognosis in Patients With CHB and NAFLD
Phase N/A · 1 location(s) · The Affiliated Nanjing Drum Tower Hospital of Nanjing Univer · NCT05766449Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study
Phase N/A · 1 location(s) · Chongqing Medical University · NCT05974904Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)
Phase 2 · 1 location(s) · Fundació Institut de Recerca de l'Hospital de la Santa Creu · NCT06599918A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis
Phase 3 · 23 location(s) · King's College London · NCT06461208
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.